Related references
Note: Only part of the references are listed.CDK4/6 Inhibitor LEE011 Is a Potential Radiation-sensitizer in Head and Neck Squamous Cell Carcinoma: An In Vitro Study
Tzong-Shyuan Tai et al.
ANTICANCER RESEARCH (2019)
MONALEESA clinical program: a review of ribociclib use in different clinical settings
Denise A. Yardley
FUTURE ONCOLOGY (2019)
Inhibition of CDK4/CDK6 Enhances Radiosensitivity of HPV Negative Head and Neck Squamous Cell Carcinomas
Eva-Leonne Gottgens et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
S. -A. Im et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Concurrent radiotherapy with palbociclib or ribociclib for metastatic breast cancer patients: Preliminary assessment of toxicity
Edy Ippolito et al.
BREAST (2019)
Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized Trial
Robert Olson et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer (vol 29, pg 1541, 2018)
G. N. Hortobagyi et al.
ANNALS OF ONCOLOGY (2019)
CDK 4/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases
Nicholas B. Figura et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
Severe acute radiation-induced enterocolitis after combined palbociclib and palliative radiotherapy treatment
Terufumi Kawamoto et al.
RADIOTHERAPY AND ONCOLOGY (2019)
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
Stephen Johnston et al.
NPJ BREAST CANCER (2019)
Safety and Efficacy of Palbociclib and Radiation Therapy in Patients With Metastatic Breast Cancer: Initial Results of a Novel Combination
Mudit Chowdhary et al.
ADVANCES IN RADIATION ONCOLOGY (2019)
First-line ribociclib plus letrozole in postmenopausal women with HR+, HER2-advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial
Wolfgang Janni et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Abemaciclib, a Selective CDK4/6 Inhibitor, Enhances the Radiosensitivity of Non-Small Cell Lung Cancer In Vitro and In Vivo
Sarwat Naz et al.
CLINICAL CANCER RESEARCH (2018)
FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Anand Shah et al.
CLINICAL CANCER RESEARCH (2018)
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3
Dennis J. Slamon et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Preliminary results of the association of Palbociclib and radiotherapy in metastatic breast cancer patients
Sophie Hans et al.
RADIOTHERAPY AND ONCOLOGY (2018)
Ribociclib plus letrozole and concomitant palliative radiotherapy for metastatic breast cancer
Icro Meattini et al.
BREAST (2018)
Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response
Chao-Yuan Huang et al.
EUROPEAN JOURNAL OF CANCER (2018)
Blocking Cyclin-Dependent Kinase 4/6 During Single Dose Versus Fractionated Radiation Therapy Leads to Opposite Effects on Acute Gastrointestinal Toxicity in Mice
Chang-Lung Lee et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
N. C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
George W. Sledge et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P. Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Combination of palbociclib and radiotherapy for glioblastoma
Shane Whittaker et al.
CELL DEATH DISCOVERY (2017)
Effects of locoregional radiotherapy in patients with metastatic breast cancer
Geovanne Pedro Mauro et al.
BREAST (2016)
Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo
Zhen Tao et al.
CLINICAL CANCER RESEARCH (2016)
Influence of Nucleoshuttling of the ATM Protein in the Healthy Tissues Response to Radiation Therapy: Toward a Molecular Classification of Human Radiosensitivity
Adeline Granzotto et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
Inhibition of CDK4/6 protects against radiation-induced intestinal injury in mice
Liang Wei et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli et al.
LANCET ONCOLOGY (2016)
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
G. N. Hortobagyi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Julia A. Beaver et al.
CLINICAL CANCER RESEARCH (2015)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn et al.
LANCET ONCOLOGY (2015)
Impact of loco-regional treatment on metastatic breast cancer outcome: A review
W. Khodari et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2013)
Inhibition of cyclin-dependent kinase 6 suppresses cell proliferation and enhances radiation sensitivity in medulloblastoma cells
Susan L. Whiteway et al.
JOURNAL OF NEURO-ONCOLOGY (2013)
Silencing CDK4 radiosensitizes breast cancer cells by promoting apoptosis
Katie R. Hagen et al.
CELL DIVISION (2013)
Can Locoregional Treatment of the Primary Tumor Improve Outcomes for Women With Stage IV Breast Cancer at Diagnosis?
David H. A. Nguyen et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Cell cycle kinases as therapeutic targets for cancer
Silvia Lapenna et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM
I Hickson et al.
CANCER RESEARCH (2004)
Share Paper
